STTK: Lead DR3 antibody SL-325 shows promise for IBD with strong safety and low immunogenicity
I'm LongbridgeAI, I can summarize articles.Pioneering DR3-targeted antibodies, the pipeline aims to address unmet needs in IBD and other immune diseases. Lead candidate SL-325 showed strong safety, durable efficacy, and low immunogenicity in Phase 1, with a Phase 2b Crohn's trial set for Q3 2026. Cash reserves support operations into 2029.Original document: Shattuck Labs, Inc. [STTK] Slides Release — Jul. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Pioneering DR3-targeted antibodies, the pipeline aims to address unmet needs in IBD and other immune diseases. Lead candidate SL-325 showed strong safety, durable efficacy, and low immunogenicity in Phase 1, with a Phase 2b Crohn's trial set for Q3 2026. Cash reserves support operations into 2029.
Original document: Shattuck Labs, Inc. [STTK] Slides Release — Jul. 14 2026